

Table 2 b: Extensive list of well-known natural compounds (drugs, lead compounds for drugs or compounds in clinical trials)) used in areas of neurological diseases, immunological or inflammatory processes, cardiovascular diseases and oncological diseases and similar compounds (Tanimoto ≥ 0.85) from the SuperNatural Database

* Anatomical Therapeutic Chemical (ATC) classification code generated by the World Health Organization (WHO) describes the therapeutic subgroup (1)

Natural Compound	Status (Reference)	Similar Compounds in SuperNatural (Tanimoto $\geq 85\%$)	Analytical Therapeutic Chemical (ATC) classification code*
Neurological disease area			
Physostigmine	Lead compound of Eserine Sulfate (2)	1	S01EB05* (Parasympathomimetics) V03AB* (Antidotes)
Huperzine	Phase III clinical trials (3)	1	V03* (All other therapeutic products)
Morphine	Lead compound of Roxanol TM (2)	9	N02AA* (Natural opium alkaloids)
Tetrahydrocannabinol	Lead compound of Tetrahydrocannabinol (2)	2	A04AD* (Other antiemetics)
Cardiovascular			
Erythromycin	Phase II clinical trials (2)	25	J01FA* (Macrolides) S01AA* (Antibiotics)
Immunological,inflammatory			
Cyclosporine	Lead compound of Sandimmune® (2)	3	L04AA* (Selective immunosuppressive agents)
Tacrolimus	Lead compound of Protopic® (2)	2	D11AX* (Other dermatologicals) L04AA* (Selective immunosuppressive agents)
Sirolimus	Lead compound of Rapamune® (2)	2	L04AA* (Selective immunosuppressive agents)
Oncological disease area			
Camptothecin	Phase I & II & III clinical trials (2)	7	L01* (Antineoplastic agents)

Homoharringtonine	Phase II clinical trials (2)	1	L01* (Antineoplastic agents)
Paclitaxel	Lead compound of Taxol® (4)	5	L01CD* (Taxanes)
Protopanaxadiol	Phase I clinical trials (2)	17	L01* (Antineoplastic agents)
Triptolide	Phase I clinical trials (2)	18	L01* (Antineoplastic agents)
Vinblastine	Lead compound of Velban® (4)	9	L01CA* (Vinca alkaloids and analogues)
Doxorubicin	Lead compound of Adriblastin® (5)	12	L01DB* (Anthracyclines and related substances)
Staurosporine	Phase I & II & III clinical trials (2)	4	L01* (Antineoplastic agents)
Fumagillin	Lead compound of CKD-732 (6)	1	L01* (Antineoplastic agents)
Halichondrin B	Phase I clinical trials (2)	5	L01* (Antineoplastic agents)

1. WHO. (2003) *World Health Organ Tech Rep Ser*, **914**, 1-126.
2. Butler, M.S. (2005) *Nat Prod Red*, **22**, 162-195.
3. (2004) *Drugs R D*, **5**, 44-45.
4. Gabai, V., Budagova, K. and Sherman, M. (2005) *Oncogene*, **24**, 3328-3338.
5. Koivusalo, R., Krausz, E., Helenius, H. and Hietanen, S. (2005) *Mol Pharmacol.*, **68**, 372-382.
6. Kim, E. and Shin, W. (2005) *Biol Pharm Bull*, **28**, 217-223.